Medicare Enrolled

Dr. Kiran Farheen, M.D.

Rheumatology · Katy, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
23920 KATY FWY STE 440, Katy, TX 77494
3462574299
Registered in NPPES since 2008
NPI: 1255594446 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Farheen from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Farheen? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Farheen

Dr. Kiran Farheen is a rheumatology specialist in Katy, TX, with 18 years of NPI registration. Based on federal Medicare data, Dr. Farheen performed 3,983 Medicare services in 2023. These records do not provide a deduplicated patient total.

Between the years covered by Open Payments, Dr. Farheen received a total of $15,457 from 37 pharmaceutical and/or device companies across 384 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Farheen is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years of NPI registration ▲ Top 45% volume in TX $15,457 industry payments

Medicare Practice Summary — 2023

Medicare Utilization ↗
3,983
Medicare services
Top 45% in TX for rheumatology
Not available
Unique patients (not deduplicated)
$32
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 3,120 $18 $30
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
472 $92 $300
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
187 $59 $225
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
70 $125 $300
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
64 $101 $350
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
53 $0 $20
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
17 $11 $50
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
2.9% high complexity
83.5% medium
13.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$15,457
Total received (2018-2024)
Avg $2,208/year across 7 years
Top 24% in TX for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
37
Companies
384
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,960
2023
$3,532
2022
$2,632
2021
$3,276
2020
$646
2019
$1,378
2018
$33

Payments by company (2024)

Janssen Biotech, Inc.
$2,420
PFIZER INC.
$191
ABBVIE INC.
$184
Amgen Inc.
$175
Novartis Pharmaceuticals Corporation
$170
GENZYME CORPORATION
$137
UCB, Inc.
$106
AstraZeneca Pharmaceuticals LP
$77
TerSera Therapeutics LLC
$75
Aurinia Pharma U.S., Inc.
$63
Mallinckrodt Hospital Products Inc.
$51
Kiniksa Pharmaceuticals International, plc
$47
Fresenius Kabi USA, LLC
$46
ANI Pharmaceuticals, Inc.
$39
Takeda Pharmaceuticals U.S.A., Inc.
$32
Alexion Pharmaceuticals, Inc.
$25
Alvogen Inc
$25
Boehringer Ingelheim Pharmaceuticals, Inc.
$24
GlaxoSmithKline, LLC.
$22
SCILEX PHARMACEUTICALS INC.
$19
E.R. Squibb & Sons, L.L.C.
$17
Genentech USA, Inc.
$13
Top 3 companies account for 70.6% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$3,102
Lilly USA, LLC
$2,722
PFIZER INC.
$2,558
Fresenius Kabi USA, LLC
$1,506
Amgen Inc.
$1,292
ABBVIE INC.
$654
Novartis Pharmaceuticals Corporation
$505
Horizon Therapeutics plc
$327
AstraZeneca Pharmaceuticals LP
$293
UCB, Inc.
$287
AbbVie, Inc.
$248
TerSera Therapeutics LLC
$218
Aurinia Pharma U.S., Inc.
$196
Mallinckrodt Hospital Products Inc.
$179
GENZYME CORPORATION
$175
GlaxoSmithKline, LLC.
$171
Alexion Pharmaceuticals, Inc.
$138
E.R. Squibb & Sons, L.L.C.
$118
AbbVie Inc.
$108
ANI Pharmaceuticals, Inc.
$102
Celgene Corporation
$75
Mallinckrodt Enterprises LLC
$69
Boehringer Ingelheim Pharmaceuticals, Inc.
$68
FIDIA PHARMA USA INC.
$48
Takeda Pharmaceuticals U.S.A., Inc.
$48
Kiniksa Pharmaceuticals International, plc
$47
DePuy Synthes Sales Inc.
$28
Alvogen Inc
$25
Actelion Pharmaceuticals US, Inc.
$24
Radius Health, Inc.
$22
SCILEX PHARMACEUTICALS INC.
$19
Antares Pharma, Inc.
$19
MEDEXUS PHARMA, INC.
$14
Cumberland Pharmaceuticals, Inc.
$14
Genentech USA, Inc.
$13
Bioventus LLC
$13
Organon LLC
$12
Top 3 companies account for 54.2% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COLOGUARD · COSENTYX · CYLTEZO · Cimzia · DUEXIS · EVENITY · Enbrel · Exogen · FORTEO · HUMIRA · HYQVIA · Humira · Hymovis · IDACIO · INFLECTRA · KEVZARA · KRYSTEXXA · LUPKYNIS · MONOVISC · NEXPLANON · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · ORTHOVISC · Otezla · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · Quzyttir · RAYOS · REDITREX · REMICADE · RINVOQ · Rasuvo · Rinvoq · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Strensiq · TALTZ · TAVNEOS · TERIPARATIDE · TREMFYA · Tavneos · Tymlos · UPTRAVI · VIMOVO · XELJANZ · XYOSTED · ZTLido
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a rheumatology specialist in Katy?
Compare rheumatologists in the Katy area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists in nearby ZIP areas
63
County median income
$113,409
Nearest hospital to ZIP centroid (approximate)
MEMORIAL HERMANN KATY HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES NPPES snapshot; verify current record
Medicare Enrollment PECOS PECOS snapshot
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Farheen is a mixed practice specialist, with moderate Medicare volume, with 18 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Farheen experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Farheen performed 3,120 denosumab injection (prolia/xgeva) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Farheen receive payments from pharmaceutical companies?
Yes. Dr. Farheen received a total of $15,457 from 37 companies across 384 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Farheen's costs compare to other rheumatologists in Katy?
Dr. Farheen's average Medicare payment per service is $32. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Farheen) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →